

## Assessment of the Effect of Fasting Ramadan on Renal Functions in Type 2 Diabetic Egyptian Patients

Moustafa B. Ata , Mohamed A. Qorny, Yasmin A. Abd El Rahman, Hytham R. Badr

### Abstract:

**Background:** Many diabetic patients insist on fasting Ramadan against medical advice. Aim: to assess how fasting Ramadan impacts kidney functions in Egyptian patients with type 2 diabetes. **Patients and Methods:** the study included 180 individuals fasted Ramadan: divided into 3 equal groups; classified into group I (Non diabetic patients with normal renal functions), group II (diabetic patients without albuminuria) and group III (diabetic patients with micro albuminuria) attending to Menoufia University Hospitals clinics. They were assessed for height, weight, blood pressure, body mass index and investigated for fasting and post prandial blood glucose , hemoglobin a1c, serum urea, creatinine, estimated GFR, and urinary albumin/creatinine ratio one month before and after Ramadan. **Results:** A significant decrease in hemoglobin A1c levels was observed in groups II and III and no change in it in Group I. Regarding kidney function tests, group I did not exhibit any significant differences, whereas groups II and III displayed a marked deterioration in these parameters, including serum urea, creatinine, and estimated GFR. No significant change in A/C ratio in Group I, but it decreased in groups II and III. **Conclusion:** Fasting Ramadan enhanced glycemic regulation in type 2 diabetic patients with no deterioration in kidney functions within group I, however, deterioration was noted in groups II and III. Patients should receive guidance on maintaining proper hydration and adopting healthy dietary changes during the period before Ramadan, and it is also advisable for them to consult their healthcare providers regarding their suitability for fasting. **Keywords:** Type 2 diabetes; Fasting Ramadan; Albuminuria; renal functions

Internal Medicine Department,  
Faculty of Medicine Menoufia  
University, Egypt.

Corresponding to:  
Dr. Yasmin A. Abd El Rahman.  
Internal Medicine Department,  
Faculty of Medicine Menoufia  
University, Egypt.  
Email: dryasmin607@gmail.com

Received:  
Accepted:

---

## Introduction

Fasting Ramadan is a fundamental religious practice performed by Muslims globally. It spans one month according to the lunar calendar. During daylight hours, Muslims refrain from consuming food and beverages, taking medications, smoking, and engaging in sexual activities, after being the primary meal eaten at nightfall, and suhoor being a light meal consumed before dawn <sup>(1)</sup>.

Even though individuals with diabetes may consume fewer meals, studies showed that their total caloric intake over the month of Ramadan tends to rise <sup>(2)</sup>.

Fasting involve of many psychological and sociological aspects. Fasting diabetic patients are at a higher risk of experiencing variations in their blood glucose levels, which can be influenced by food type, content, and amount they eat, consistency in medication intake, and changes in their daily physical activity <sup>(3)</sup>.

Diabetic kidney disease (DKD) is the world's leading cause of end-stage renal disease .It is a clinical syndrome characterized by increase urine albumin excretion and or reduction in the estimated glomerular filtration rate in diabetic patients who lack indicators of other renal disease <sup>(4)</sup>.

Physicians should advise diabetic patients who fast about risks of fasting such as hypoglycemia, hyperglycemia, diabetic ketoacidosis and dehydration. Diabetic patients with moderate to severe CKD should be monitored during Ramadan to prevent any harmful consequences <sup>(5)</sup>.

Certain research indicated that patients with diabetic kidney disease (DKD) generally tolerated, remained safe, and experienced positive results during fasting Ramadan <sup>(6)</sup>.

Conversely, other research revealed negative impacts on kidney health in tropical climates characterized by high heat and humidity <sup>(7)</sup>.

The IDF-DAR Practical Guidelines 2021, established by the International Diabetes Federation, are the authoritative guidelines

for preventing complications related to Fasting in individuals with chronic kidney disease and diabetes <sup>(8)</sup>.

---

## Patients and methods

A cross-sectional study assessed 180 Egyptian patients, divided into 3 groups of equal numbers; non-diabetic patients with normal renal functions (Group I), diabetic patients with a GFR higher than 60 ml/min/1.73 m<sup>2</sup> and no albuminuria (Group II), and diabetic patients with a GFR between (60 ml/min/1.73 m<sup>2</sup> and 90 ml/min/1.73 m<sup>2</sup>) with micro albuminuria (30-300) mg/g (Group III).

Every patient planning to fast Ramadan (2024) will experience an average fasting duration of 14 hours, approximately from 4:30 AM to 6:30 PM, with surrounding temperatures ranging from 25°C to 30°C. Patients attending Endocrine & diabetic clinics in Menoufia University hospitals. Samples collected according to inclusion and exclusion criteria one month before and after Ramadan from February 2024 to May 2024, an informed consent was obtained from all individual participants included in the study, and the Research Ethical Committee of Menoufia University granted approval for the study of IRP number {4/2023 INTM 42}.

Type 1 diabetic patient, DKD Patients stage 3 or more, Patients with history of heart failure or gestational diabetes and Patients with autoimmune kidney disease were not included in this study.

Every patient undergoes a comprehensive medical history assessment that includes their age, gender, chronic illnesses, and a clinical examination, which encompasses the measurement their height, weight, blood pressure, and body mass index in kg/m<sup>2</sup>.

## Laboratory investigations

Laboratory tests are hemoglobin A1c(HbA1c), fasting blood glucose (FPG), 2-hour postprandial blood glucose (2-h PPG) , kidney function tests (serum creatinine, blood urea and urinary albumin/creatinine ratio ) should be

evaluated one month prior to Ramadan, followed by a repeat of these tests within one month after Ramadan.

Assessments were performed in the clinical biochemistry lab, utilizing commercial kits that were modified for the auto analyzer, with blood glucose tests conducted using the glucose oxidase and peroxidase methods<sup>(9)</sup>.

Berthelot's method was used to measure serum urea,<sup>(10)</sup> Creatinine levels were assessed using the alkaline Jaffe's Picrate technique;<sup>(11)</sup> the typical range for normal creatinine is from 0.7 to 1.4 mg/dL and levels of urea were between 18 to 45 mg/dL<sup>(12)</sup>. HbA1c levels were determined using the ion exchange resin technique with HbA1c diagnostic kits from Asritha Diatech<sup>(13)</sup>.

Urine micro albumin levels were assessed using radioimmunoassay with Diagnostic Products Corp., Los Angeles, CA, USA, is the manufacturer of the DPC Coat-A-Count kit. The alkaline picrate method was used to assess the content of creatinine in the urine.<sup>(14)</sup>

Urinary albumin/creatinine Ratio was measured, it is classified into normal (A/C Ratio <30 µg/mg) or micro albuminuria (A/C Ratio between 30 and 300 µg/mg) and macro albuminuria (A/C Ratio greater than 300 µg/mg)<sup>(15)</sup>.

The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI creatinine-based eGFR equation

$CKD-EPI_{21} = 142 \times \min(Scr/\kappa, L) \alpha \times \max(Scr/\kappa, L)^{-1.200} \times 0.9938Age \times 1.012$  [if female], where: Scr represents standardized serum creatinine measured in mg/dL

$\kappa$  equals 0.9 for males 0.7 for females, and  $\alpha$  is set at -0.302 for males -0.241 for females.<sup>(16)</sup>

### Statistical analysis

Continuous variables are represented as the average  $\pm$  standard deviation (SD) along with the range. Using quantitative data to compare more than two separate groups with quantitative data, One Way Analysis of Variance (ANOVA) was

utilized. To determine the differences among the studied groups, the post-hoc Tukey's HSD test was conducted. The Student's t-test was employed for comparing two independent groups with quantitative data. The paired t-test assessed the changes in laboratory data before and after Ramadan. Categorical variables were expressed as frequency and percentage, analyzed using the Chi-squared test. Linear regression analysis was applied to examine the independent variables influencing the estimated GFR. A P value of less than 0.05 was deemed statistically significant. R Software version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses.

### Results

Patients are managed to fast for about 30 days during Ramadan. Regarding fasting patients, none experienced any acute illnesses while fasting, and there were no new clinical symptoms or signs reported.

The groups under study were matched by sex ( $p =$ , 132). The average age was (49.91  $\pm$  9.75) years and the average duration of diabetes was (10.88  $\pm$  5.71) years for group II and group III, The cases were age matched ( $p =$ , 140) duration of diabetes was statistically different ( $p <$  0.001).

Prior to the month of Ramadan, there was a highly significant difference ( $p <$  0.001) among the three groups concerning SBP, creatinine, UACR, and estimated GFR.

In the comparison of each pair of groups using Tukey's test, groups II and III exhibited notably higher blood pressure and creatinine levels than group I. A significantly reduced estimated glomerular filtration rate (GFR) was observed in group III when compared to both groups II and I. The Urinary Albumin to Creatinine Ratio was also significantly elevated in group III in relation to groups II and I (**Table, 1**).

Following Ramadan, there were no significant differences in SBP, DBP, FPG, 2hPPG, weight, and BMI across all the groups examined. Additionally, no

statistically significant differences were observed in Hemoglobin A1C, urea, creatinine, GFR, and UACR in group I (the healthy group) before and after Ramadan.

Analysis using Tukey's test revealed that group III had significantly elevated levels of SBP, DBP, creatinine, HbA1c, and UACR when compared with group II. Additionally, group I exhibited significantly reduced levels of FBS, 2hPG, HbA1C, serum urea, creatinine, and UACR in comparison to both groups (II and III) (Table, 2).

In examining each group results before and after Ramadan, groups II and III exhibited a noteworthy reduction in HbA1c and estimated GFR. There was a significant rise in creatinine levels and a minor increase in urea, alongside a decrease in UACR (Table, 3).

Groups II and III displayed a notable negative correlation between estimated GFR and HbA1c ( $p = 0.001$ ) prior to fasting, as well as a significant negative correlation was found between estimated GFR and the duration of diabetes ( $p = 0.001$ ) following fasting.

**Table (1)**—A comparison of laboratory data among all researched groups prior to Ramadan fasting.

		Group I N= 60	Group II N= 60	Group III N= 60	F	P-value	Tukey's HSD
<b>Body weight</b>	Mean (SD)	76.32 (2.73)	82.75 (3.00)	84.69 (3.01)	38.08	<0.001*	P1=<0.001* P2=<0.001* P3=0.183
	Range	70-80	78-90	80-90			
<b>BMI</b>	Mean (SD)	29.25	31.74 (1.08)	31.88 (1.03)	31.31	<0.001*	P1=0.032* P2=0.030* P3=0.931
	Range	(1.15) 26.9-32	30.4-34.6	30-33.8			
<b>SBP</b>	Mean (SD)	122.11 (9.7)	133.75 (8.47)	137.69 (8.81)	13.16	<0.001*	P1=0.001* P2=<0.001* P3=0.482
	Range	6) 110-145	) 120-145	120-150			
<b>DBP</b>	Mean (SD)	78.42 (6.47)	83.12 (4.79)	83.46 (3.76)	6.569	0.013*	P1=0.032* P2=0.030* P3=0.984
	Range	) 70-90	) 80-90	) 80-90			
<b>FBS (mg/dL)</b>	Mean ±	83.23 ±	151.88 ±	182.43 ±	256.8	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	7.10 70-96	29.78 120-272	29.53 132-296			
<b>PPBS (mg/dL)</b>	Mean ±	122.35 ±	216.82 ±	299.45 ±	276	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	8.92 104-138	50.11 150-359	50.30 183-420			
<b>HbA1c</b>	Mean ±	5.19 ± 0.22	8.73 ± 1.31	10.57 ± 1.25	405.4	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	4.6-5.5	6.7-12.1	8.5-15.1			
<b>Serum urea (mg/dL)</b>	Mean ±	31.06 ±	35.17 ± 5.04	43.50 ± 7.32	66.97	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	5.38 15-40	22-49	21.6-65			
<b>Serum creatinine (mg/dL)</b>	Mean ±	0.71 (0.06)	0.82 ± 0.10	1.07 ± 0.12	221.8	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	0.6-0.8	0.7-1.1	0.8-1.3			
<b>eGFR (mL/min/1.73 m2)</b>	Mean ±	110.83 ±	100.08 ±	73.07 ± 9.28	187.7	<0.001*	P1=<0.001* P2=<0.001* P3=<0.001*
	SD Range	9.99 90-133	13.31 67-125	60-89			
<b>Urinary albumin-creatinine ratio</b>	Mean ±	7.10 ± 1.74	21.55 ± 6.99	204.50 ±	447.2	<0.001*	P1=0.124 P2=<0.001* P3=<0.001*
	SD Range	4-12	8-29	69.44 26-290			

Data are presented as mean ± standard deviation. FBS; Group I, Healthy group; Group II, Normoalbuminuria group; Group III, Microalbuminuria group; systolic blood pressure, DBP; diastolic blood pressure; FBS, fasting blood sugar; PPBS, 2-hour postprandial blood sugar; HbA1c, glycosylated hemoglobin; eGFR, estimated glomerular filtration rate; t, paired t-test; N, number of participants. \*  $p < 0.05$  is considered significant.

**Table (2):** Comparison of laboratory results among all examined groups following fasting Ramadan.

		<b>Group I N= 60</b>	<b>Group II N= 60</b>	<b>Group III N= 60</b>	<b>F</b>	<b>P-value</b>	<b>Tukey's HSD</b>
<b>Body weight</b>	Mean (SD )	76.61 (2.88)	82.50 (3.35)	84.46 (3.07)	28.97	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> P3=0.217
	Range	71-82	77-91	79-91			
<b>BMI</b>	Mean (SD )	29.38 (1.26)	31.69 (1.23)	31.77 (1.02)	22.35	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> P3=0.984
	Range	27.3-32.8	29.6-35	30.4-34.2			
<b>SBP</b>	Mean (SD )	120.68 (7.71)	132.81 (8.56)	135.77 (7.03)	17.44	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> P3=0.574
	Range	110-135	120-145	120-145			
<b>DBP</b>	Mean (SD )	78.53 (3.67)	81.50 (2.94)	82.31 (2.59)	6.569	<b>0.003*</b>	<b>P1=0.022*</b> <b>P2=0.005*</b> P3=0.775
	Range	70-85	80-90	80-85			
<b>FBS (mg/dL)</b>	Mean ± SD	81.2 ± 8.29	152.05 ± 31.09	185.93 ± 31.78	251.4	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	68-96	115-250	126-280			
<b>PPBS (mg/dL)</b>	Mean ± SD	124.8 ± 8.84	231.25 ± 54.84	315.02 ± 53.37	275.6	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	104-137	145-370	184-425			
<b>HbA1c</b>	Mean ± SD	5.20 ± 0.25	8.02 ± 1.26	9.83 ± 1.29	295.5	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	4.6-6	6-11				
<b>Serum urea (mg/dL)</b>	Mean ± SD	32.83 ± 6.19	42.65 ± 6.43	53.22 ± 8.88	117.9	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	18-45	22-58	27-76			
<b>Serum creatinine (mg/dL)</b>	Mean ± SD	0.74 ± 0.09	1.07 ± 0.12	1.34 ± 0.15	389.7	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	0.6-0.9	0.9-1.4				
<b>eGFR (mL/min/1.73 m2)</b>	Mean ± SD	108.22 ± 12.31	75.38 (13.06)	55.5 ± 8.48	323.8	<b>&lt;0.001*</b>	<b>P1=&lt;0.001*</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	79-133	50-116	43-73			
<b>Urinary albumin-creatinine ratio</b>	Mean ± SD	7.27 ± 1.76	9.92 ± 3.36	102.72 ± 35.39	419.9	<b>&lt;0.001*</b>	<b>P1= 0.76</b> <b>P2=&lt;0.001*</b> <b>P3=&lt;0.001*</b>
	Range	5-17	25-110	395			

N: Number of participants in the group  
SD: Standard deviation  
BMI: Body Mass Index  
SBP: Systolic Blood Pressure  
DBP: Diastolic Blood Pressure  
FBS: Fasting Blood Sugar (mg/dL)  
PPBS: Postprandial Blood Sugar (mg/dL)  
HbA1c: Glycated Hemoglobin (percentage)  
eGFR: Estimated Glomerular Filtration Rate (mL/min/1.73 m<sup>2</sup>)  
P-value: Probability value (statistical significance)  
Tukey's HSD: Tukey's Honest Significant Difference test  
P1, P2, P3: Pairwise comparisons between groups in Tukey's HSD analysis

**Table (3):** Analysis of laboratory data from all studied groups before and after the Ramadan fasting period.

Dependent: Group	Group I N=60		P- value	Group II N=60		P-value	Group III N=60		P-value
	Before	After		Before	After		Before	After	
<b>Body weight</b>	76.32 (2.73) 70-80	76.61 (2.88) ) 71-82	0.752	82.75 (3.0 0) 78-90	82.50 (3.3 5) 77-91	0.825	84.69 (3 .01) 80-90	84.46 (3 .07) 79-91	0.848
<b>BMI</b>	29.25 (1.15) 26.9-32	29.38 (1.26 ) 27.3-32.8	0.739	31.74 (1.0 8) 30.4-34.6	31.69 (1.2 3) 29.6-35	0.916	31.88 (1 .03) 30-33.8	31.77 (1 .02) 30.4- 34.2	0.776
<b>SBP</b>	122.11 (9.76 ) 110-145	120.68 (7.7 1) 110-135	0.622	133.75 (8. 47) 120-145	132.81 (8. 56) 120-145	0.758	137.69 ( 8.81) 120-150	135.77 ( 7.03) 120-145	0.544
<b>DBP</b>	78.42 (6.47) 70-90	78.53 (3.67 ) 70-85	0.951	83.12 (4.7 9) 80-90	81.50 (2.9 4) 80-90	0.257	83.46 (3 .76) 80-90	82.31 (2 .59) 80-85	0.371
<b>FBS (mg/dL)</b>	83.23 ± 7.10 70-96	81.2 ± 8.29 68-96	0.152	151.88 ± 29.78 120-272	152.05 ± 31.09 115-250	0.976	182.43 ± 29.53 132-296	185.93 ± 31.78 126-280	0.533
<b>PPBS (mg/dL)</b>	122.35 ± 8.92 104-138	124.8 ± 8.84 104-137	0.133	216.82 ± 50.11 150-359	231.25 ± 54.84 145-370	0.135	299.45 ± 50.30 183-420	315.02 ± 53.37 184-425	0.103
<b>HbA1c</b>	5.19 ± 0.22 4.6-5.5	5.20 ± 0.25 4.6-6	0.757	8.73 ± 1.31 6.7-12.1	8.02 ± 1.26 6-11	<b>0.003*</b>	10.57 ± 1.25 8.5-15.1	9.83 ± 1.29 7.7-14.2	<b>0.002*</b>
<b>Serum urea (mg/dL)</b>	31.06 ± 5.38 15-40	32.83 ± 6.19 18-45	0.096	35.17 ± 5.04 22-49	42.65 ± 6.43 22-58	<b>&lt;0.001</b> *	43.50 ± 7.32 21.6-65	53.22 ± 8.88 27-76	<b>&lt;0.001*</b>
<b>Serum creatinine (mg/dL)</b>	0.71 (0.06) 0.6-0.8	0.74 ± 0.09 0.6-0.9	0.057	0.82 ± 0.10 0.7-1.1	1.07 ± 0.12 0.9-1.4	<b>&lt;0.001</b> *	1.07 ± 0.12 0.8-1.3	1.34 ± 0.15 1-1.61	<b>&lt;0.001*</b>
<b>eGFR (mL/min/1.73 m2)</b>	110.83 ± 9.99 90-133	108.22 ± 12.31 79-133	0.204	100.08 ± 13.31 67-125	75.38 (13.06) 50-116	<b>&lt;0.001</b> *	73.07 ± 9.28 60-89	55.5 ± 8.48 43-73	<b>&lt;0.001*</b>
<b>Urinary albumin- creatinine ratio</b>	7.10 ± 1.74 4-12	7.27 ± 1.76 5-17	0.603	21.55 ± 6.99 8-29	9.92 ± 3.36 25-110	<b>&lt;0.001</b> *	204.50 ± 69.44 26-290	102.72 ± 35.39 81-395	<b>&lt;0.001*</b>

Data are expressed as mean ± SD. FBS; Group I, Healthy group; Group II, Normoalbuminuria group; Group III, Microalbuminuria group; systolic blood pressure, DBP; diastolic blood pressure; FBS, fasting blood sugar; PPBS, 2-hour postprandial blood sugar; HbA1c, glycosylated hemoglobin; eGFR, glomerular filtration rate; t, paired t-test; N represents the count of patients. \* (p < 0.05) indicates statistical significance.

## Discussion

Every year endocrinologists face their duties towards fasting Muslim diabetic patients around the world. They concern about risks of fasting such as hypoglycemia, hyperglycemia, diabetic ketoacidosis, dehydration and its side effects on renal functions.<sup>(17)</sup>

We assessed the impact of fasting the month of Ramadan on kidney function in Egyptian patients with type 2 diabetes. The findings of this research indicated that there was no variation in BMI among the three studied groups following fasting Ramadan. This is consistent with the results reported by<sup>(18)</sup> who found no changes in BMI when comparing

measurements taken before and after fasting.

On the other side, <sup>(19)</sup> indicated that the body mass index reduced following Ramadan as the weight decreased, this was agreed with <sup>(20)</sup> who recorded a reduction in body weight following fasting Ramadan among diabetic patients in Algeria and Malaysia, but <sup>(21)</sup> demonstrated a notable rise in bodily mass. This might be explained by differences in sample sizes also the varying feeding habits among these communities.

The present study indicated that there was no notable variation in blood pressure, as neither systolic nor diastolic blood pressure showed any change in all groups following Ramadan. This finding is consistent with the results of <sup>(22)</sup> who found no significant alteration in systolic blood pressure after Ramadan. Additionally, <sup>(23)</sup> reported that there was no substantial decrease in systolic or diastolic blood pressure at the conclusion of fasting when compared to measurements taken prior to fasting.

On the contrary, <sup>(24)</sup> revealed that blood pressures were significantly lowered after month of Ramadan comparing results with before it.

In comparison data of glucose parameters before and after Ramadan, The current study demonstrated that there were no notable alterations in glucose indicators across all groups examined. Consistent with our results, <sup>(25)</sup> found that glucose parameters (fasting and postprandial) levels remained the same following Ramadan fasting.

Also, <sup>(26)</sup> reported that there was no marked reduction in fasting blood sugar, and the levels of 2-hour postprandial blood sugar, average blood glucose, and Hemoglobin A1c remained unchanged.

In this study HbA1c did not change in group I (healthy group), while it decreased in group II and group III, <sup>(27)</sup> showed a marked reduction in HbA1c after fasting.

In this study, there is a significant rise in serum urea and creatinine concentrations

in groups II and III as well as a significant decrease in estimated GFR in these groups after fasting Ramadan, while no significant change in these parameters in group I. This aligns with the findings of <sup>(28)</sup> who demonstrated a notable increase in serum creatinine levels and a significant reduction in estimated GFR among patients with Type 2 DM with normal kidney functions, whether albuminuria is present or not, after fasting the month of Ramadan. Moreover, <sup>(29)</sup> reported that third of Chronic Kidney Disease patients encountered a deterioration in their kidney functions either while fasting during Ramadan or within three months afterward.

On the other hand, <sup>(30)</sup> noted that the serum creatinine level showed no significant variation following fasting Ramadan, and the estimated glomerular filtration rate (GFR) of individuals with chronic kidney disease (CKD) did not significantly alter during the Ramadan fast.

It was reported that there no marked alteration in serum creatinine levels, along with a marked enhancement in the estimated GFR during and following the fasting period of Ramadan <sup>(31)</sup>.

A study was conducted on CKD individuals with Stage 3 or higher, categorized into two groups (those who fasted and those who did not), and it was determined that fasting did not correlate with a heightened risk of decline in kidney function among these individuals, except for elderly patients who may be at higher risk. <sup>(32)</sup>.

As regarding Urinary A/C Ratio in this study, a significant decrease in A/C ratio after fasting Ramadan in groups II and III was noted, but not changed in healthy group I <sup>(33)</sup> reported a significant decrease in micro albuminuria during Ramadan, This suggests that the health of the glomerular membrane was not adversely impacted by fasting Ramadan.

It was shown that there was no significant change in the Urinary Albumin Creatinine Ratio in patients with type 2 diabetes after

fasting during Ramadan, and it remained low six weeks after Ramadan<sup>(34)</sup>.

On the other side,<sup>(35)</sup> the study demonstrated that the A/C ratio was elevated in individuals with both micro- and macro albuminuria, suggesting that fasting negatively impacted albuminuria in diabetic patients.

This research found a notable negative association between HbA1c levels and estimated GFR in groups II and III prior to Ramadan. This finding aligns with<sup>(36)</sup> who indicated that patients with reduced estimated GFR exhibited higher HbA1c levels, even after adjusting for age, body mass index, hemoglobin levels, and using erythropoietin.

In this research, a notable negative correlation was found between the duration of diabetes and the estimated GFR in groups II and III following Ramadan. This finding aligns with the work by<sup>(37)</sup> which indicated that the length of time a person has diabetes is a significant risk factor that greatly influences the occurrence of diabetic kidney disease.

Furthermore,<sup>(38)</sup> demonstrated that the average duration of diabetes was considerably longer in individuals who progressed to diabetic kidney disease compared to those who did not.

---

## Conclusion

Fasting Ramadan enhanced glycemic control in type 2 diabetic patients, but there was a deterioration in kidney function among both albuminuric and normoalbuminuric patients. It is essential for patients to receive guidance on proper hydration and nutritious dietary changes throughout Ramadan, and they should also seek advice from their doctors to evaluate their capacity to engage in fasting.

## Conflict of interest

None of the contributors declared any conflict of interest

---

## Reference

1. Al-Awadhi AM, Bash A, AlGharabali B, Al-Hashel M, Jamaani F. Religious practices, fasting, and individuals' trading behavior: a natural experiment. *Journal of Islamic Accounting and Business Research*. 2024 Sep 20.
2. Alnemery A, Alshahrani A, Al-Jabari S, Alruwaili M, Almalki H, Alhamed R, et al. Management of diabetes during the holy month of Ramadan: An Updated Review. *Journal of Health Informatics in Developing Countries*. 2023 May 16;17(01).
3. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. *Diabetes Care*. 2023 Feb 1;46(2):441-9.
4. Sinha SK, Nicholas SB. Pathomechanisms of Diabetic Kidney Disease. *Journal of Clinical Medicine*. 2023 Nov 27;12(23):7349.
5. Kamrul-Hasan AB, Alam MS, Kabir MA, Chowdhury SR, Hannan MA, Chowdhury EU, et al. Risk stratification using the 2021 IDF-DAR risk calculator and fasting experience of Bangladeshi subjects with type 2 diabetes in Ramadan: The DAR-BAN study. *Journal of Clinical & Translational Endocrinology*. 2023 Mar 1;31:100315.
6. Alobaidi S. Ramadan Fasting and Its Impact on Patients With Chronic Kidney Disease: Insights and Guidelines. *Cureus*. 2024 Apr;16(4).
7. Malik S, Bhanji A, Abuleiss H, Hamer R, Shah SH, Rashad R, et al. Effects of fasting on patients with chronic kidney disease during Ramadan and practical guidance for healthcare professionals. *Clinical Kidney Journal*. 2021 Jun 1;14(6):1524-34.
8. Hassanein M, Afandi B, Ahmedani MY, Alamoudi RM, Alawadi F, Bajaj HS, et al. Diabetes and Ramadan: practical guidelines 2021. *Diabetes research and clinical practice*. 2022 Mar 1;185:109185.
9. Alqobaisi A, Alharbi Z, Albakiri F, Alfouzan RK, Farh I, Mansour M. Interference of Mannose and Galactose in Glucose Assay by the Glucose Oxidase/Peroxidase Method. *Journal of Advances in Medicine and Medical Research*. 2023 Dec 11;35(23):372-9.
10. Deepak KS, Balapure A, Priya PR, Kumar PS, Dubey SK, Javed A, et al. Development of a microfluidic device for the dual detection and quantification of ammonia and urea from the blood serum. *Sensors and Actuators A: Physical*. 2024 Apr 16;369:115174.



11. Choosongsang P, Bhornsrivathanyou N, Aiadsakun P, Choosongsang P, Bodhikul A, Yamsuwan Y, et al. Glucose interference in serum and urine samples with various creatinine concentrations measured by the Jaffe kinetic method. *EJIFCC*. 2023 Apr;34(1):57.
12. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of biochemical parameters of patients with type 2 diabetes mellitus based on age and gender in Umuahia. *Asian Journal of Dental and Health Sciences*. 2023 Jun 15;3(2):32-6.
13. Mukherjee S, Yadav P, Ray SK, Jadhav AA, Wakode SL. Clinical Risk Assessment and Comparison of Bias between Laboratory Methods for Estimation of HbA1c for Glycated Hemoglobin in Hyperglycemic Patients. *Current Diabetes Reviews*. 2024 Sep 1;20(7):62-70.
14. Carvajal CA, Tapia-Castillo A, Uslar T, Fardella CE. Apparent Mineralocorticoid Excess. In *Hydro Saline Metabolism: Epidemiology, Genetics, Pathophysiology, Diagnosis and Treatment* 2023 Oct 13 (pp. 317-349). Cham: Springer International Publishing.
15. Khadka S, Yadav GK, Subedi P, Amgain K, Sharma A, Joshi R. Association of urinary albumin-to-creatinine ratio with lipid abnormalities and glycemic control in patients with type 2 diabetes mellitus. *Annals of medicine and surgery*. 2023 Sep 1;85(9):4329-33.
16. Munch PV, Heide-Jørgensen U, Jensen SK, Birn H, Vestergaard SV, Frøkiær J, et al. Performance of the race-free CKD-EPI creatinine-based eGFR equation in a Danish cohort with measured GFR. *Clinical Kidney Journal*. 2023 Dec;16(12):2728-37.
17. Shaltout I, Abdelwahab AM, El Meligi A, Hammad H, Abdelghaffar S, Elbahry A, et al. Risk stratification in people with diabetes for fasting during Ramadan: consensus from Arabic Association for the Study of Diabetes and Metabolism. *Current Diabetes Reviews*. 2024 Sep 1;20(7):1-22.
18. Abdallah H, Khalil M, Farella I, John Britto JS, Lanza E, Santoro S, et al. Ramadan intermittent fasting reduces visceral fat and improves gastrointestinal motility. *European Journal of Clinical Investigation*. 2023 Sep;53(9):e14029.
19. Al-Jafar R, Wahyuni NS, Belhaj K, Ersi MH, Boroghani Z, Alreshidi A, et al. The impact of Ramadan intermittent fasting on anthropometric measurements and body composition: evidence from LORANS study and a meta-analysis. *Frontiers in Nutrition*. 2023 Jan 17;10:1082217.
20. Elmajnoun HK, Faris ME, Abdelrahim DN, Haris PI, Abu-Median AB. Effects of ramadan fasting on glycaemic control among patients with type 2 diabetes: Systematic review and meta-analysis of observational studies. *Diabetes Therapy*. 2023 Mar;14(3):479-96.
21. Najafi MT, Sadoogh Abbasian A, Mohammadi H, Abbasi MR, Khatami MR, Ghafari A, et al. Alteration in body water compartments following intermittent fasting in Ramadan. *Frontiers in Nutrition*. 2023 Aug 14;10:1232979.
22. Nomany MS, Rashid HU, Alam MR. Fasting Ramadan in Chronic Kidney Disease, Kidney Transplant and Dialysis Patients. *OFFICIAL JOURNAL OF BANGLADESH RENAL ASSOCIATION*. 2023 Jul;5(2):60.
23. Dahmouni S. Comparative assessment of the effects of Ramadan fasting on the anthropometric biochemical and haematological parameters of athletes sedentary individuals and sedentary smokers (Doctoral dissertation) 2024.
24. Elmajnoun HK, Faris ME, Abdelrahim DN, Haris PI, Abu-Median AB. Effects of ramadan fasting on glycaemic control among patients with type 2 diabetes: Systematic review and meta-analysis of observational studies. *Diabetes Therapy*. 2023 Mar;14(3):479-96.
25. Jarrar Y, Abdul-Wahab G, Mosleh R, Abudahab S, Jarrar Q, Hamdan A, et al. Does Ramadan intermittent fasting affect the fasting blood glucose level among type II diabetic patients?. *Journal of Clinical Medicine*. 2023 Oct 18;12(20):6604.
26. Shaukat A, Zaidi A, Anwar H, Kizilbash N. Mechanism of the antidiabetic action of *Nigella sativa* and Thymoquinone: a review. *Frontiers in Nutrition*. 2023 Sep 25;10:1126272.
27. Ibrahim M, Barker MM, Ahmad E, Ahmed A, Annabi FA, Ba-Essa EM, et al. Optimizing Ramadan fasting: A randomised controlled trial for people with type 2 diabetes during Ramadan applying the principles of the ADA/EASD consensus. *Diabetes/Metabolism Research and Reviews*. 2023 Mar;39(3):e3604.
28. Asmamaw T, Genet S, Menon M, Tarekegn G, Chekol E, Geto Z, Lejisa T, Habtu W, Getahun T, Tolcha Y. Early detection of renal impairment among patients with type 2 diabetes mellitus through evaluation of serum cystatin C in comparison with serum creatinine levels: a cross-sectional study. *Diabetes, Metabolic Syndrome and Obesity*. 2020 Dec 3:4727-35.
29. Haroon A, Riaz M, Rabbani B, Saeed A. Safety of fasting in diabetic and non-diabetic patients with stable chronic kidney disease

- during Ramadan. *Pakistan Journal of Medical Sciences*. 2024 Mar;40(4):563.
30. Megahed AF, Abdel-Gawad SM, El-Bahnasawy NA, Sayed-Ahmed N. Ramadan fasting in chronic kidney disease patients: a descriptive observational study. *Asian Journal of Medicine and Health*. 2023 Nov 27;21(11):309-20.
31. Islam M. Impact of Ramadan fasting on eGFR in patients with late stage chronic kidney disease. *Journal of Health Sciences and Medicine*. 2023;6(5):1016-21.
32. Hafidh K, Besheya TA, Elmehdawi R, Beshyah SA. Ramadan fasting and diabetes (2022): the year in review. *Journal of Diabetes and Endocrine Practice*. 2023 Jul;6(03):104-17.
33. Mohammad MS, Mahdy MM, Ibrahim NA, Jalil NA. Effects of Ramadan fasting on diabetic nephropathy in type 2 diabetic patients. *QJM: An International Journal of Medicine*. 2023 Jun 1;116(Supplement\_1):hcad069-474.
34. Abusahmin H, Abdelgadir E, Eledrisi MS, Hafidh K, Beshyah SA. Diabetes and Ramadan Fasting (2023): The Year in Review. *Journal of Diabetes and Endocrine Practice*. 2024 Apr 11.
35. Abushady MM, Samy M, Bekhet M, Abdullah A. Effect of Ramadan fasting on renal function in patients with type 2 diabetes. *Diabetes Research and Clinical Practice*. 2019 Jul 1;153:176-83.
36. Arnold F, Kappes J, Rottmann FA, Westermann L, Welte T. HbA1c-dependent projection of long-term renal outcomes. *Journal of Internal Medicine*. 2024 Feb;295(2):206-15.
37. Vestergaard AH, Jensen SK, Heide-Jørgensen U, Frederiksen LE, Birn H, Jarbøl DE, et al. Risk factor analysis for a rapid progression of chronic kidney disease. *Nephrology Dialysis Transplantation*. 2024 Jan 2;gfad271.
38. Cheng T, Wang X, Han Y, Hao J, Hu H, Hao L. The level of serum albumin is associated with renal prognosis and renal function decline in patients with chronic kidney disease. *BMC nephrology*. 2023 Mar 15;24(1):57.

**To cite this article:** Moustafa B. Ata , Mohamed A. Qorny, Yasmin A. Abd El Rahman, Hytham R. Badr. Assessment of the Effect of Fasting Ramadan on Renal Functions in Type 2 Diabetic Egyptian Patients. *BMFJ XXX*, DOI: 10.21608/bmfj.2024.335622.2253.